Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibody-targeted photodynamic therapy.

George L Mayo1, Robert F Melendez, Neeru Kumar

  • 1Department of Ophthalmology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, USA.

American Journal of Ophthalmology
|December 4, 2003
PubMed
Summary

Conjugating verteporfin to an antibody against vascular endothelial growth factor is feasible. This verteporfin conjugate effectively destroys targeted cells, showing promise for therapeutic applications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Torsion-Induced Traumatic Optic Neuropathy (TITON): A physiologically relevant animal model of traumatic optic neuropathy.

PloS one·2025
Same author

Torsion-Induced Traumatic Optic Neuropathy (TITON): A Physiologically Relevant Animal Model of Traumatic Optic Neuropathy.

bioRxiv : the preprint server for biology·2024
Same author

Outcomes After Implantation of a Trifocal Toric Intraocular Lens Using Intraoperative Aberrometry, Digital Image Tracking, and Femtosecond Laser.

Clinical ophthalmology (Auckland, N.Z.)·2024
Same author

Comparison of Astigmatism Prediction Accuracy for Toric Lens Implantation from Two Swept-Source Optical Coherence Tomography Devices.

Clinical ophthalmology (Auckland, N.Z.)·2022
Same author

Kidney-limited AL amyloidosis: a case report and review of the literature.

Journal of community hospital internal medicine perspectives·2021
Same author

Regulations, Generics, and Disruptive Technologies in Ophthalmology: What Every Scientist Needs to Know.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2021

Area of Science:

  • Bioconjugation Chemistry
  • Photodynamic Therapy
  • Ophthalmology

Background:

  • Verteporfin (Visudyne) is a photosensitizer used in photodynamic therapy.
  • Vascular Endothelial Growth Factor (VEGF) plays a crucial role in angiogenesis and is a target in various diseases.
  • Targeted drug delivery aims to enhance therapeutic efficacy and reduce side effects.

Purpose of the Study:

  • To determine the feasibility of conjugating verteporfin to an antibody targeting VEGF.
  • To evaluate the photosensitizing properties and cytotoxic effects of the verteporfin-antibody conjugate.

Main Methods:

  • Rabbit polyclonal antibody against VEGF was chemically conjugated to verteporfin.
  • Spectroscopic analysis confirmed the integrity of verteporfin's properties post-conjugation.

Related Experiment Videos

  • In vitro studies on VEGF-expressing endothelial cells assessed cell viability after laser activation of the conjugate.

    • Main Results:

    • The verteporfin-VEGF antibody conjugate retained verteporfin's fluorescence properties.
    • Laser exposure of conjugate-treated cells resulted in significant cell death (6% viability at 1 hour, 4% at 24 hours).
    • The conjugate demonstrated potent cytotoxicity, comparable to or exceeding verteporfin alone under laser irradiation.

    Conclusions:

    • Verteporfin can be successfully conjugated to an anti-VEGF antibody without compromising its photosensitizing ability.
    • The resulting conjugate effectively eliminates targeted cells, indicating its potential as a targeted photodynamic therapy agent.
    • This approach offers a promising strategy for localized treatment of VEGF-mediated conditions.